PD-1免疫疗法-话题@MedSci

#PD-1免疫疗法#

27篇内容 | 1102人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1647716, encodeId=5c16164e716ed, content=<a href='/topic/show?id=01e9139044b' target=_blank style='color:#2F92EE;'>#PD-1免疫疗法#</a>, objectTitle=FDA授予默沙东PD-1免疫疗法Keytruda第4个突破性药物资格：经典型霍奇金淋巴瘤（cHL）, objectType=article, longId=66949, objectId=653e669497b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=653e669497b, replyNumber=0, likeNumber=41, createdTime=2016-10-09, rootId=0, userName=crystal0570, userId=d33523471030, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=653e669497b, moduleTitle=FDA授予默沙东PD-1免疫疗法Keytruda第4个突破性药物资格：经典型霍奇金淋巴瘤（cHL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=653e669497b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647715, encodeId=3f4e164e71569, content=<a href='/topic/show?id=01e9139044b' target=_blank style='color:#2F92EE;'>#PD-1免疫疗法#</a>, objectTitle=FDA受理PD-1免疫疗法Keytruda治疗晚期非小细胞肺癌的申请, objectType=article, longId=64509, objectId=589064509ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=589064509ee, replyNumber=0, likeNumber=40, createdTime=2016-06-20, rootId=0, userName=crystal0570, userId=d33523471030, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=589064509ee, moduleTitle=FDA受理PD-1免疫疗法Keytruda治疗晚期非小细胞肺癌的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=589064509ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647712, encodeId=db53164e712de, content=<a href='/topic/show?id=01e9139044b' target=_blank style='color:#2F92EE;'>#PD-1免疫疗法#</a>, objectTitle=PD-1免疫疗法监管重大里程碑：百时美Opdivo获欧盟批准，系欧洲PD-1疗法, objectType=article, longId=52397, objectId=b2135239e88, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2135239e88, replyNumber=0, likeNumber=41, createdTime=2016-01-04, rootId=0, userName=crystal0570, userId=d33523471030, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2135239e88, moduleTitle=PD-1免疫疗法监管重大里程碑：百时美Opdivo获欧盟批准，系欧洲PD-1疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2135239e88)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647713, encodeId=5656164e71374, content=<a href='/topic/show?id=01e9139044b' target=_blank style='color:#2F92EE;'>#PD-1免疫疗法#</a>, objectTitle=PD-1免疫疗法Opdivo治疗鳞状肺癌表现出持续生存获益（CheckMate-017，CheckMate-063研究）, objectType=article, longId=56040, objectId=67d956040cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67d956040cd, replyNumber=0, likeNumber=30, createdTime=2015-10-15, rootId=0, userName=crystal0570, userId=d33523471030, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67d956040cd, moduleTitle=PD-1免疫疗法Opdivo治疗鳞状肺癌表现出持续生存获益（CheckMate-017，CheckMate-063研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67d956040cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647710, encodeId=6761164e710b7, content=<a href='/topic/show?id=01e9139044b' target=_blank style='color:#2F92EE;'>#PD-1免疫疗法#</a>, objectTitle=SABCS 2014：PD-1免疫疗法展现三阴乳腺癌治疗潜力, objectType=article, longId=44419, objectId=618d444197c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=618d444197c, replyNumber=0, likeNumber=26, createdTime=2015-04-22, rootId=0, userName=crystal0570, userId=d33523471030, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=618d444197c, moduleTitle=SABCS 2014：PD-1免疫疗法展现三阴乳腺癌治疗潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=618d444197c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647711, encodeId=b88e164e711db, content=<a href='/topic/show?id=01e9139044b' target=_blank style='color:#2F92EE;'>#PD-1免疫疗法#</a>, objectTitle=默沙东牵手卫材深度挖掘PD-1免疫疗法Keytruda临床潜力, objectType=article, longId=47787, objectId=c6754e78774, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6754e78774, replyNumber=0, likeNumber=49, createdTime=2015-11-12, rootId=0, userName=crystal0570, userId=d33523471030, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6754e78774, moduleTitle=默沙东牵手卫材深度挖掘PD-1免疫疗法Keytruda临床潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6754e78774)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647709, encodeId=ebb7164e70942, content=<a href='/topic/show?id=01e9139044b' target=_blank style='color:#2F92EE;'>#PD-1免疫疗法#</a>, objectTitle=SABCS 2014：默沙东PD-1免疫疗法Keytruda展现三阴乳腺癌（TNBC）治疗潜力, objectType=article, longId=43990, objectId=6f7c43990df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f7c43990df, replyNumber=0, likeNumber=38, createdTime=2015-09-04, rootId=0, userName=crystal0570, userId=d33523471030, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f7c43990df, moduleTitle=SABCS 2014：默沙东PD-1免疫疗法Keytruda展现三阴乳腺癌（TNBC）治疗潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f7c43990df)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-1免疫疗法

2020-05-29

crystal0570 (审核中...)

前往app查看评论内容

#PD-1免疫疗法#

FDA授予默沙东PD-1免疫疗法Keytruda第4个突破性药物资格：经典型霍奇金淋巴瘤（cHL）

2016-10-09

crystal0570 (审核中...)

前往app查看评论内容

#PD-1免疫疗法#

FDA受理PD-1免疫疗法Keytruda治疗晚期非小细胞肺癌的申请

2016-06-20

crystal0570 (审核中...)

前往app查看评论内容

#PD-1免疫疗法#

PD-1免疫疗法监管重大里程碑：百时美Opdivo获欧盟批准，系欧洲PD-1疗法

2016-01-04

crystal0570 (审核中...)

前往app查看评论内容

#PD-1免疫疗法#

PD-1免疫疗法Opdivo治疗鳞状肺癌表现出持续生存获益（CheckMate-017，CheckMate-063研究）

2015-10-15

crystal0570 (审核中...)

前往app查看评论内容

#PD-1免疫疗法#

SABCS 2014：PD-1免疫疗法展现三阴乳腺癌治疗潜力

2015-04-22

crystal0570 (审核中...)

前往app查看评论内容

#PD-1免疫疗法#

默沙东牵手卫材深度挖掘PD-1免疫疗法Keytruda临床潜力

2015-11-12

crystal0570 (审核中...)

前往app查看评论内容

#PD-1免疫疗法#

SABCS 2014：默沙东PD-1免疫疗法Keytruda展现三阴乳腺癌（TNBC）治疗潜力

2015-09-04

科室
- - 订阅+
  - 更多科室
工具
服务